Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials

A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)

(2016) M. Johnson et al.   ANNALS OF ONCOLOGY

SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting

(2016) E. Dean et al.   ANNALS OF ONCOLOGY

NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

(2016) M. Socinski et al.   ANNALS OF ONCOLOGY

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

(2016) F. Barlesi et al.   ANNALS OF ONCOLOGY

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

(2016) A Kotsakis et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer withFGFR1amplification: A single-arm, phase 2 study

(2016) Sung Hee Lim et al.   CANCER

Targeting the fibroblast growth factor receptor family in cancer

(2016) Niamh Hallinan et al.   CANCER TREATMENT REVIEWS

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

(2016) Suresh S. Ramalingam et al.   CLINICAL CANCER RESEARCH

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

(2016) Rafael Caparica et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies

(2016) Murali Janakiram et al.   Immunotherapy

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

(2016) Patricia Mucci LoRusso   JOURNAL OF CLINICAL ONCOLOGY

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

(2016) Mark M. Awad et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

(2016) Xuewen Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

(2016) Corey J. Langer et al.   Journal of Thoracic Oncology

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth

(2016) M. C. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

(2016) P. Tomasini et al.   ONCOLOGIST

Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo

(2016) Baoan Chen et al.   OncoTargets and Therapy

Recent advances in the management of pulmonary sarcomatoid carcinoma

(2016) Elaine Shum et al.   Expert Review of Respiratory Medicine

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

(2015) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

(2015) Cristina Saura et al.   CANCER RESEARCH

Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer

(2015) Parames Thavasu et al.   CANCER RESEARCH

Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

(2015) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

(2015) D. R. Gandara et al.   CLINICAL CANCER RESEARCH

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

(2015) B. Besse et al.   EUROPEAN JOURNAL OF CANCER

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

(2015) Nick Thatcher et al.   LANCET ONCOLOGY

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

(2015) Takehito Shukuya et al.   LANCET ONCOLOGY

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

(2015) David E. Gerber et al.   LUNG CANCER

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

(2014) Dejan Juric et al.   CANCER RESEARCH

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study

(2014) Govind K Babu et al.   OncoTargets and Therapy

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Genomics of Squamous Cell Lung Cancer

(2013) M. Rooney et al.   ONCOLOGIST

Advances in using PARP inhibitors to treat cancer

(2012) Shivaani Kummar et al.   BMC Medicine

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

(2011) Robert Pirker et al.   LANCET ONCOLOGY

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

(2010) Eric B. Haura et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Faye M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

(2009) G. Scagliotti et al.   ONCOLOGIST

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY